Loading company…
Siena-based developer of antibody-based targeted therapeutics for cancer and chronic inflammation.
Based in Siena, Italy and founded in 1996, Philogen S.p.A. develops targeted therapeutics for cancer and chronic inflammation. Its antibody-based approach delivers therapeutic payloads, such as cytokines, to the site of disease. Its research uses platforms including antibody libraries and DNA-encoded chemical libraries. Its stage is listed as Series C.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in